Lumito

2,88 SEK

-2,21 %

Mindre end 1K følgere

LUMITO

NGM Growth Market

Biotechnology & Pharmaceuticals

Health Care

Oversigt

Finansielt overblik og estimater

Ejerskab

Dividend

Investorkonsensus

-2,21 %

-15,32 %

-56,77 %

-58,93 %

-86,63 %

-96,13 %

-99,17 %

-99,15 %

-98,82 %

Lumito is a Swedish company that develops and markets systems for tissue and biomarker analysis in digital pathology, built on upconverting nanoparticle technology. The company targets healthcare facilities, research and the pharmaceutical sector. The company was formed in 2010 as a spinoff from a research group at Lund University's Department of Atomic Physics and Laser Center. Lumito is headquartered in Lund.

Markedsværdi

9,89 mio. SEK

Aktieomsætning

41,98 t SEK

Omsætning

-

EBIT %

-

P/E

-

Udbytteafkast, %

-

Omsætning og EBIT-margin

Omsætning t

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender

20.8

2026

Delårsrapport Q2'26

29.10

2026

Delårsrapport Q3'26

23.2

2027

Årsrapport '26

Alle

Selskabsmeddelelser

ViserAlle indholdstyper

Selskabsmeddelelse7.5.2026, 06.30

Lumito AB publishes Interim Report Q1 2026

Selskabsmeddelelse5.5.2026, 09.00

Invitation to webinar in connection with Lumito AB’s interim report for Q1 2026

Selskabsmeddelelse4.5.2026, 08.00

Simpler biomarker workflows without compromising sensitivity: new white paper shows how researchers gain reproducible, quantitative IHC results in fewer steps

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto

Følgere og notifikationer om fulgte virksomheder

Analytikerkommentarer og anbefalinger

Værktøj til at sammenligne aktier og andre populære værktøjer

Selskabsmeddelelse9.4.2026, 06.30

Lumito’s CRO strategy generates revenue through collaboration with Truly Labs AB

Selskabsmeddelelse2.4.2026, 06.30

Lumito and OracleBio initiate a pilot project to explore the combination of high-sensitivity tissue imaging and advanced image analysis

Selskabsmeddelelse18.3.2026, 08.00

Lumito and Tethis complete proof-of-concept study demonstrating compatibility between Lumito’s UCNP imaging and Tethis’ SmartBioSurface® slides

Selskabsmeddelelse12.3.2026, 08.15

Lumito and Offspring Biosciences initiate pilot study to combine automated, standardised workflows with high‑sensitivity tissue analysis

Selskabsmeddelelse10.3.2026, 14.15

Lumito publishes equity research report on Lumito

Selskabsmeddelelse10.3.2026, 10.45

Lumito presents at Analyst Group’s and InFront Direkt Studios’ capital markets day

Selskabsmeddelelse20.2.2026, 07.30

Lumito AB publishes year-end report 2025

Selskabsmeddelelse18.2.2026, 08.20

Lumito and Atlas Antibodies enter strategic partnership to advance high-resolution tissue imaging

Selskabsmeddelelse17.2.2026, 14.00

Invitation to webinar in connection with Lumito AB’s year-end report for 2025

Selskabsmeddelelse3.2.2026, 08.40

Lumito initiates pilot project with leading professor in urological cancer research at Lund University

Selskabsmeddelelse30.1.2026, 14.45

Lumito announces timetable for reverse share split and recalculated terms for outstanding warrants of series TO7

Selskabsmeddelelse29.1.2026, 08.15

Lumito receives patent approval in India

Selskabsmeddelelse28.1.2026, 07.30

Two Swedish research customers place orders for Lumito’s SCIZYS Erbium Kit

Selskabsmeddelelse23.1.2026, 13.50

Lumito’s technology presented at The Pathological Society of Great Britain & Ireland Winter Meeting 2026

Selskabsmeddelelse20.1.2026, 15.30

Changes to the Nomination Committee ahead of Lumito’s Annual General Meeting 2026

Selskabsmeddelelse13.1.2026, 08.30

Analyst Group initiates coverage of Lumito

Selskabsmeddelelse12.1.2026, 08.15

Lumito receives order from Swedish research unit

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.